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Highlights. 
• Ketogenic diet treatment in infants with refractory epilepsy is effective and can be 
done safely. 
• Ketogenic diet must be adjusted to specific nutritional requirements of infants. 
• Monitoring during initiation and follow up is required by a multidisciplinary team. 
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Abstract  
The ketogenic diet (KD) is an established, effective non-pharmacologic treatment for drug 
resistant childhood epilepsy. For a long time, the KD was not recommended for use in infancy 
(under the age of 2 years) because this is such a crucial period in development and the 
perceived high risk of nutritional inadequacies. Indeed, infants are a vulnerable population 
with specific nutritional requirements. But current research shows that the KD is highly 
effective and well tolerated in infants with epilepsy. Seizure freedom is often achieved and 
maintained in this specific patient group. 
There is a need for standardised protocols and management recommendations for clinical use. 
It is desirable that consensus is reached with regard to guidance on how the diet should be 
administered and in whom. In April 2015, a project group of 5 experts was established in 
order to create a consensus statement regarding the clinical management of the KD in infants. 
The manuscript was reviewed and amended by a larger group of 10 international experts in 
the KD field. 
The resulting recommendations include patient selection, pre-KD counseling and evaluation, 
specific nutritional requirements, preferred initiation, monitoring of adverse effects at 
initiation and follow-up, evaluation and KD discontinuation. This paper highlights 
recommendations based on best evidence, combined with expert opinions and gives directions 
for future research. 
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1.                    Introduction/background 
The ketogenic diet (KD) is a non-pharmacologic treatment for children with drug resistant 
epilepsy. The efficacy of the KD has been established by several multicenter studies and one 
randomized controlled trial. The randomized trial that further established the efficacy of KD 
was conducted in children and adolescents aged 2 to 16 years [1]. The diet may be 
administered in one of several ways and each may be valid. An international protocol for its 
implementation and subsequent follow-up management in children has been published [2] and 
recently updated (ILAE 2015) [3] .  
For a long time, the KD was not recommended for use in infancy (under the age of 2 years) in 
view of it being such a crucial period of development and the perceived high risk of 
nutritional inadequacies. This was based on the knowledge of immaturity of lipase activity, 
liver function and lipid metabolism and the difficulty of achieving and maintaining ketosis.  
 
The first reports by Nordli et al in a small group of infants showed the KD to be effective and 
safe [4]. A KD formula with ratio 3:1 is now available making the diet easier to administer in 
this group as first or second line treatment. The most recent study by Dressler et al showed the 
KD to be highly effective and well tolerated in infants with epilepsy. Seizure freedom appears 
to be often achieved and maintained in this age group[5].  
 
Because international KD guidelines do not contain specific advice for infants, 
recommendations for optimal practice in this group are needed. Infants are a vulnerable 
population with specific nutritional requirements. It is therefore desirable that consensus is 
reached with regard to guidance on how the diet should be administered and in whom. 
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2.                 Methods. 
At the Dietary Management of Inherited Metabolic Diseases  (DMIMD) conference 2015 in 
London an initial meeting was held with the goal of starting a working group of experts in KD 
treatment in infancy. A group of five experts (i.e two pediatric neurologist and three 
dietitians, see appendix I) discussed issues with regard to specific recommendations for this 
group of patients and designed the framework based on subjects they found applicable. 
During teleconference calls several subjects were addressed.  A larger group of international 
experts (i.e. 3 pediatric neurologists and 7 dietitians, see appendix I) on KD treatment in 
infants were asked to send their guidelines or, in absence of recent published literature on 
subjects, information based on their professional or center's experience. These experts also 
reviewed the full manuscript of the recommendations. After two rounds of review, consensus 
was reached on the final text. 
 
The questions to be answered were: 
-Which epilepsy syndromes in infancy benefit most from KD treatment? 
- How should KD initiation be considered in infants? 
- Which version of KD is feasible and safe in infancy and how should the KD be initiated? 
- What are the dietary prescriptions for infants in respect to their specific nutritional 
requirements? 
- How should the KD be monitored during treatment at baseline and follow up  and which are 
the most important adverse effects to be expected? 
- How should the diet be implemented in emergency situations? 
- After what period of time should efficacy of KD treatment be evaluated and/or the diet 
discontinued? 
- What are the future directions for research? 
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3.                 Epilepsy syndromes in infancy where KD is of benefit. 
Management of epilepsy in infancy is challenging based on the characteristics of the epilepsy 
and its impact on neurodevelopment of the child. This implies early, aggressive and optimal 
treatment is warranted. As a non-pharmacological treatment KD is currently used in infants 
with refractory epilepsy syndromes (see table 1) such as  infantile spasms (West syndrome) 
resistant to first line medication [6-10], Ohtahara syndrome [11, 12], epilepsy of infancy with 
migrating seizures [13] and resistant epilepsy with focal seizures awaiting epilepsy surgery. 
There are also other conditions for which the KD is the treatment of choice such as glucose 
transporter type 1 (GLUT-1) deficiency [14] and pyruvate dehydrogenase complex (PDHC) 
deficiency [15] . 
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Table 1. Indications and contra indications of KD in infants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.                  Preparing for treatment. 
Treatment with the KD is demanding for families and requires a high degree of medical and 
dietetic monitoring because of possible side effects and restrictiveness. A multidisciplinary 
team is highly recommended (pediatric neurologist/pediatrician, epilepsy nurse, dietitian and 
close cooperation with pharmacy).  
Indications  
Epilepsy: 
- Refractory epilepsy after use of 2      
  anti-epileptic drugs (AEDs):  
  i.e.    -  West syndrome  
           -  Ohtahara syndrome 
           -  with focal seizure waiting for      
              epilepsy surgery 
 
Metabolic diseases: 
- GLUT-1 deficiency 
- PDHC deficiency 
            optional: 
- Mitochondrial diseases  
Contra-indications  
Absolute: 
- Fatty acid oxidation deficiencies  
  (VLCAD, LCHAD, MCAD, 
   OCTN2, CPT1, CPT2) 
- Pyruvate carboxylase deficiency     
  and other gluconeogenesis defects 
  (fructose 1,6 diphosphatase    
  deficiency) 
- Glycogen storage diseases  
  (except   type 2) 
- Ketolysis defects 
- Ketogenisis defects 
- Porphyria 
- Prolonged QT syndrome or other 
   cardiac diseases 
- Liver, kidney or pancreatic   
   insufficiency 
- Hyperinsulinism 
Relative   
  - Inability to maintain adequate 
    nutrition 
- Surgical focus identified by 
    neuroimaging and video EEG 
    monitoring 
- Parent or caregiver non    
   compliance 
- Growth retardation 
- Severe gastrointestinal reflux 
 - Familial hypercholesterolemia 
7 
 
At baseline detailed information is obtained on the medical, nutritional and biochemical status 
of the infant. After a positive decision an individualized KD and step by step plan will be 
designed. 
 
5.                  Dietary prescription.  
 
5.1                Which diet to choose and how to initiate. 
KD is a high fat (71-90 % energy) and carbohydrate restricted (5-19 % energy) diet that 
contains adequate amount of protein to support growth. Clinical practice shows the classical 
version of the KD with a 3:1 ratio is routinely used in infants in order to meet protein 
requirements. This means that for every 3 grams of fat there is 1 gram of combined protein 
and carbohydrate.  Several studies show the range of KD ratio used is  2.5-4:1 with respect of 
tolerance, ketosis and side effects [6-8, 10].    
Information in the literature on how the KD should be initiated in infants is scarce. Raju et al 
(2011) showed in a randomized trial of 38 infants that a 2.5:1 ratio KD was as effective as 4:1 
ratio KD but less side effects were seen [16]. Pires et al (2013) showed in a prospective trial 
of 17 infants receiving a KD during hospitalisation that a 3:1 (some 4:1) ratio was very 
effective and tolerated well. Diet initiation was performed by a non-fasting protocol with 
daily steps of increasing calories and ratio [7]. 
Information from expert teams show infants are admitted to hospital for diet initiation 
performed without fasting and by an individualized step by step plan. Most centers start with 
a 1.0:1 ratio with full calories, increasing the ratio on a daily basis to 3:1 based on tolerance. 
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Recommendations: all young infants (< 12 months) should be admitted to hospital. Diet 
initiation should be undertaken without fasting and a stepwise start commencing with a 1:1 
ratio. A build to a classical KD with 3:1 ratio is recommended. The diet can be adjusted to a 
lower ratio (2.5 or 2:1) or higher ratio (3.5 or 4:1) based on level of ketosis and tolerance. A 
KD formula with ratio 3:1 can be used purely or combined with breast milk. Careful 
calculation to check individual requirements are met is highly recommended especially when 
a 4:1 ratio is applied. 
 
5.2                Energy. 
The energy requirements of infants with epilepsy may vary greatly. There is no consensus in 
the literature on how to calculate energy requirements in infants below 6 months of age.  
Often a percentage (75% - 100%) of the recommended daily allowance (RDA) of energy is 
used; sometimes an individual calculation is reported based on dietary history [2, 4, 17].  
 For infants with severe disability such as encephalopathy with epilepsy and severe motor 
involvement, a calculation of the expected energy requirement based only on the Schofield 
formula is not very accurate below 10 kg and/or age 12 months.  
The total energy requirement depends on the physical activity that may be influenced by 
epileptic seizures, the anti-epileptic drug (AED) used and possibly the degree of spasticity or 
frequency of muscle spasm during epileptic seizures [18]. The RDAs are recommendations 
for groups of healthy children, making them less suitable for the individual with epilepsy but 
still the only validated recommendations available. 
 
Recommendations: for infants the energy requirements have to be based on the intake 
recorded in the food diary, compared with the RDA for age and gender and recent growth.  
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If there is a recent decline in the growth curve or failure to thrive an additional amount of 
energy is necessary. Using the ideal weight/age or weight/height should be considered to 
ensure catch up growth. If infants have gained a large amount of weight (e.g. after 
adrenocorticotropic hormone (ACTH) use), it is important to determine the most appropriate 
weight/age or weight/ height to be used for an adequate diet calculation. In individual cases 
resting energy expenditure (REE) can be measured with a ventilated hood on which factors 
for (catch up) growth and physical activity level (PAL) will be multiplied. The energy intake 
has to be adjusted frequently (sometimes on weekly basis) based on evaluation of growth 
curve, changes in level of activity and/or illness.    
 
Table 2. Energy requirements for an infant on the KD based on RDA*.  
Age/months Weight/kg Kcal/kg/day 
1-3  3.8- 5.9   100-95 
4-6  6.0 -7.9     95-85 
7-12  8.0- 10.0    85-80 
* RDA from Austria, France, Germany, The Netherlands, UK, USA. 
 
5.3                Fat. 
The classical KD is based on long chain triglyceride (LCT) and works with different ratios. 
Most infants use the classical KD at a ratio of 3:1. Based on individual tolerance and/or level 
of ketosis, a different ratio may be used (2:1 – 4:1).  
Use of medium chain triglyceride (MCT) in infants will be limited. In older infants  use of 
MCT 50% emulsion mixed with a (low fat) milk product (50-50) or a little amount of MCT 
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20% emulsion drink will be possible. The amount of MCT is tailored based on level of ketosis 
and tolerance. 
The amount of total MCT well tolerated by the infant will be around 10-25% of daily energy 
intake. 
 
5.4                Protein. 
The protein requirements of infants with epilepsy are the same as in healthy infants. There is 
no consensus in the literature (primarily the classical KD) with respect to protein intake.  
Often, 10 % energy combined protein and carbohydrate is assumed in which 1 gram of 
protein per kg body weight is recommended; sometimes a protein intake of 5-7 % energy is 
reported or reference is made to the RDAs. 
With the classical KD, achieving an adequate protein intake in the ratio is at the expense of 
the allowed quantity of carbohydrate. Therefore for the young child with psychomotor delay, 
with a realistic chance of growth retardation, a ratio of 3:1 is usually chosen [4, 19]. 
 
Recommendations: for infants the protein intakes based on RDA are advised (see table 3). 
If there is a recent decline in the growth curve or failure to thrive an adequate intake of 
protein is important. Using the ideal weight/age or weight/height should be considered to 
ensure catch up growth. 
If infants have gained a large amount of weight it is important to determine the most 
appropriate weight/age or weight/height to be used for adequate diet calculation. 
Aim for the optimal amount of protein and check that the amount of protein is above the 
minimal World Health Organisation (WHO) recommendation [20, 21] 
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The diet must be adjusted frequently (sometimes on weekly basis) based on weight gain. 
 
Table 3. Recommended daily protein intake for an infant on the KD 
               based on RDA or WHO/FAO. 
Age/months Weight/kg 
(use ideal 
weight/age) 
Protein g/kg/day 
during  KD* 
Protein/g/kg/day 
WHO/FAO  
1-3  3.8- 5.9  2.0-1.6 1.77-1.36** 
4-6  6.0 -7.9  1.5-1.3 1.24-1.12** 
7-12  8.0- 10.0  1.2-1.1 1.12-0.86*** 
*       Based on average RDA from Austria, France, Germany, The Netherlands, UK, USA. 
**     WHO 2007:  safe level for growth +1.96 SD   
***   FAO 2013 
 
5.5               Carbohydrate. 
The permitted quantity of carbohydrate follows from the calculation of energy and protein 
requirements and the establishment of the necessary quantity of fat. 
The allowed quantity of carbohydrate is divided throughout the day to prevent adverse effects 
such as hypoglycaemia or excessive ketosis. Artificial sweeteners should be avoided in 
infants. 
Introduction of solid foods, when age and developmentally appropriate, will increase the 
amount of fibre since constipation is a frequent adverse effect of the KD. The potential 
presence of resorbable carbohydrate in medication and supplements should not be overlooked.  
 
Recommendations:  the treating physician consults the pharmacist for suitable (alternative) 
sugar free medication. 
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5.6                Fluid. 
In the past, the KD has been combined with a fluid restriction. It was believed that mild 
dehydration improved the efficacy of the KD. Theories that a fluid restriction influenced the 
pH, electrolytes or ketone concentrations of the blood and brain have been abandoned after 
various studies.  According to Homer et al, no mechanism has been found that shows that 
over hydration has a negative effect on epileptic seizures [22]. 
 
Recommendations: fluid restriction might add to the development of kidney stones so an 
adequate hydration is required. An age and weight appropriate fluid intake is advised based 
on RDA, with fluid offered throughout the day. The fluid intake should be individually 
calculated and adjusted frequently based on weight gain and biochemistry results (e.g. urine 
calcium: creatinine ratio). 
 
Table 4. Recommended daily fluid intake based on RDA*. 
Age/months Weight/kg ml/kg/day 
1-3  3.8- 5.9   150-140 
4-6  6.0 -7.9  120-110 
7-12  8.0- 10.0  100-  90 
* Based on average of RDA from Austria, France, Germany, The Netherlands, UK, USA. 
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5.7               Vitamins and minerals. 
The classical KD contains insufficient micronutrients [23, 24] The potential presence of 
absorbable / resorbable carbohydrate in vitamin/mineral supplements however should not be 
overlooked. It is known that various anticonvulsants have interactions with some minerals and 
vitamins, for example, influencing the absorption of folic acid and the metabolism of calcium 
and vitamin D [22]. 
 
Recommendations: by means of adequate supplementation, the intake of micronutrients 
should be individually calculated corresponding to reference intakes for age and weight. 
When starting to wean off a formula diet, micronutrient intake should be assessed and 
supplementation commenced as necessary (for example when formula intake contributes to 
less than 80% of energy requirements). 
 
6.                 Treatment phase. 
6.1               Baseline monitoring  
Prior to the start of KD, laboratory and urine checks are strongly advised to ensure there are 
no pre-existing contra-indications or deficiencies (table 5) . 
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Table 5. Advised baseline monitoring [2] 
Investigation  
(baseline) 
 
Essential : Recommended 
Blood: 
Full blood count 
Blood:  
Vitamins A, E, B12 
Renal profile (includes 
sodium, potassium, urea, 
creatinine, bicarbonate 
and albumin)  
Zinc, selenium, copper 
  
Liver profile  Folate, ferritin 
Calcium, phosphate, 
magnesium   
 
Glucose   
Vitamin D    
Lipid profile (repeat 
with fasting if elevated) 
 
Free and acylcarnitine 
profile  
 
Urine:  
calcium:creatinine ratio 
haematuria , organic 
acids 
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6.2.              Monitoring during diet initiation.    
6.2.1            General. 
During diet initiation weight, nutritional intake, tolerance (i.e gasto intestinal disturbances, 
vomiting, etc.) are checked on a daily basis. Height and head circumference are measured at 
baseline.  
While on a KD the infant can continue bottle feeding. In daily practice the majority of infants 
with severe epilepsy have feeding difficulties and may need an enteral tube feed at diet 
initiation to achieve their requirements. 
It is possible to continue using a limited amount of expressed breastmilk combined/mixed 
with ketogenic 3:1 formula. If there is no expressed breastmilk a limited amount of standard 
infant formula can be used to combine/mix with the ketogenic formula. 
This may be given by bottle and/or tube.  
In some cases (i.e. the young infant) breastfeeding may be possible after a controlled amount 
of ketogenic formula is given, which highly depends on seizure reduction and on level of 
ketosis. In this situation the use of ketogenic 3:1 formula is recommended. In some of these 
cases ketogenic 4:1 formula may be necessary, but use this only after careful calculation and 
monitoring. In some cases (i.e. the young infant) breastfeeding on demand may be possible 
but this highly depends on seizure frequency and on level of ketosis. 
 
6.2.2            Glucose. 
There is a risk of hypoglycaemia during diet initiation although uncommon in the absence of 
a metabolic disease. During initiation blood glucose should be checked twice daily (or more 
based on symptoms of hypoglycemia) and frequency must be adjusted based on tolerance. 
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Hypoglycemia is defined as glucose levels below of 2-2.5 mmol/l (approximately 40mg/dl) 
and should be treated immediately with 2-4 grams of carbohydrates. Infants with blood 
glucose > 3mmol/l but showing symptoms of hypoglycaemia (see figure 1) should also be 
treated in the same way. Blood glucose should be re-checked after 15-20 minutes and if not 
improved treatment should be repeated. 
 
6.2.3              Ketones. 
During transition to a ketogenic feeding regime or ketogenic food, the level of ketone bodies 
in the blood will increase. Monitoring of ketones will ensure a therapeutic level is reached 
without risking symptoms of excess ketosis (see figure 1). Ketones can be measured in blood 
or urine. Blood testing using a ketometer is recommended during diet initiation as this is more 
accurate and unaffected by urine dilution or any possible alterations in water homeostasis that 
may occur in very young infants. Blood ketones should be checked twice daily using a finger 
or heel prick. Hyperketosis is defined as 5 mmol/l or higher in blood and  should be treated 
with 2-4 grams of carbohydrates. Blood ketones should be re-checked after 15-20 minutes and 
if not improved treatment should be repeated. 
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 Figure 1: Overview of preparation, initiation and treatment of Ketogenic Diet in Infants 
 
  EEG: electroencephalogram, GI: GastroIntestinal. 
 
6.2.4              Gastro-intestinal complaints. 
Gastro-intestinal problems such as vomiting, nausea, diarrhea, and abdominal discomfort are 
common side effects of the KD [16, 25], however they can usually be alleviated with dietary 
manipulation and by altering the step by step initiation plan. 
There is a risk that children with pre-existing gastro oesophageal reflux will have symptoms 
exacerbated by a high fat regime in view of delayed gastric emptying. Optimising anti-reflux 
medication will help alleviate the symptoms. 
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Constipation is the most common reported complication of the KD and may already be 
present prior to diet initiation. Despite dietary changes to help lessen the problem many 
children need additional treatment with medication. 
When the amount of fat is increased gradually the risk of adverse effects will be limited. 
 
6.3               Monitoring and adverse effects during follow up. 
 
6.3.1            Glucose/ketones. 
There is a risk of hypoglycaemia, acidosis, dehydration and high levels of ketones on 
commencing a KD [25] with increased risk of excess ketosis and metabolic acidosis with 
concurrent use of carbonic anhydrase inhibitors (for example, topiramate or zonisamide) [26]. 
 
6.3.2           Gastro intestinal complaints. 
Gastro-intestinal problems such as vomiting, nausea, diarrhea and abdominal discomfort are 
common on-going side effects of the KD however can usually be alleviated with dietary 
manipulation, see section 6.2.4. [27, 28].  
 
6.3.3           Growth.  
There is evidence of impaired growth in children on the KD [29, 30]; younger children may 
be more at risk [19]. Long-term follow up of children treated with the KD in the past suggests 
that although growth does improve after the diet is discontinued, height gain can still be 
below expected  [31]. Although growth retardation appears to be a problem in children on 
both classical and MCT KDs despite the latter providing a significantly higher protein intake 
[32], a prescribed protein-to-energy ratio of at least 1.5 g protein/100kcal has been suggested 
to help prevent growth faltering [33]. 
19 
6.3.4           Nutritional deficiencies. 
Children with drug resistant epilepsy are at risk of insufficient vitamin D status prior to 
starting a KD [34] and although levels can be normalised on diet therapy with vitamin D 
supplementation, a decline in both whole body and spine bone mineral content while on the 
KD has been reported [35] despite reduction in anticonvulsant medication.  
Selenium deficiency has been reported in children on the KD [36] with the risk of impaired 
myocardial function [37].  
Hypomagnesaemia has also been seen [25], and may be a particular problem in children on 
the classical KD despite micronutrient supplementation [23].  
Vitamin C deficiency has been reported in one child on the KD [38] but plasma levels of fat 
soluble vitamins A and E can often be raised as a consequence of a high fat intake [23]. A fall 
in carnitine status of children and young adults during the first few months of the KD has 
been seen with some cases requiring supplementation [39], although levels tended to 
normalise with time on diet therapy.  
 
6.3.5           Cardiovascular.  
Plasma lipid levels can often be elevated by the KD and significant increases in atherogenic 
apoB-containing lipoproteins have been reported in children after 6 months of KD [40]. 
Although there is evidence of a trend back towards normal with time on the KD [41], this 
raises concern about long term adverse effects on vascular function. Studies suggest that 
while arterial stiffness may increase initially [42], the changes in arterial function observed 
within the first year of KD treatment are not significant after 24 months and appear to be 
reversible [43]. Further studies are required to investigate this issue. 
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6.3.6.          Kidney stones.  
The use of KD in infants might increase the risk of kidney stones compared to older children. 
In addition to the age factor, the presence of hypercalciuria also increases the risk for the 
development of kidney stones [44]. Uric acid, calcium oxalate, calcium phosphate or mixed 
composition stones have been reported in up to 7% of children on the KD [44-46]. Risk may 
be higher with long-term treatment [29] and concurrent use of carbonic anhydrase inhibitors 
[47]. The daily oral intake of citrate potassium that theoretically alkalinizes the urine and 
solubilizes urine calcium can be suggested to prevent kidney stones, in particular in the 
patients with cumulating risk factors. A retrospective study comparing patients treated by KD 
with or without daily potassium citrate supplement has suggested a preventive effect [48].  
 
6.3.7              Other side effects.  
Other reported, but rare, side effects of the KD are increased infection risk, bruising, raised 
serum uric acid, fractures, pancreatitis, lipid-aspiration pneumonia, and cardiac abnormalities 
[25, 37, 49-51].  
 
6.3.8            Adverse effects of the ketogenic diet reported in infants  
Most commonly seen in infants were gastro-intestinal disturbances especially constipation 
and reflux, altered lipid levels, renal stones and acidosis.  Most side effects were transient and 
could be controlled without diet withdrawal by a high level of monitoring as recommended in 
table 6 A and B.  However Eun et al  reported that 37% of their group of 43 infants 
discontinued the KD due to complications [6]. Most studies are based on retrospective data, 
which implies a lower quality assessment of side effects. 
For summary of reported side effects in infants see supplementary material [4-9, 52-54]. 
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Table 6 A. Advised clinical monitoring during follow up. 
Assessment of KD efficacy by seizure 
diary and medication review, also any 
other observed benefits 
Every follow up visit. 
Assessment of KD tolerance and side 
effects including questions about bowel 
function, sleep, behavior and appetite 
Every follow up visit. 
Weight, height and head circumference Every follow up visit 
Blood and urine testing As detailed in Table 6B.  
Tests should be repeated more 
frequently if show abnormal results or 
there are other concerns 
Renal ultrasound  After 12 months on the KD. As an 
extra test if clinically indicated by 
haematuria in 3 consecutive tests or if 
an infant shows unexplained irritability  
(at baseline and during KD). 
EEG When clinically indicated. 
ECG At baseline and if clinically indicated. 
Dual Energy X-ray Absorptiometry 
(DEXA)  
Due to the limited reference data for 
this young age group, routine 
monitoring with DEXA scans is not 
recommended in infants 
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Table 6 B. Advised biochemical monitoring during follow up. 
Investigation    Frequency of monitoring  
Essential :   
Blood: 
Full blood count 
 
6 weeks, 3 months, 6 months, then every 6 
months  
Renal profile (includes sodium, potassium, 
urea, creatinine, bicarbonate and albumin)  
6 weeks, 3 months, 6 months, then every 6 
months 
Liver profile  6 weeks, 3 months, 6 months, then every 6 
months 
Calcium, phosphate, magnesium   6 weeks, 3 months, 6 months, then every 6 
months 
Glucose  6 weeks, 3 months, 6 months, then every 6 
months 
Vitamin D   after 3 months, 6 months, then every 6 
months  
 Lipid profile (repeat with fasting if elevated) after 3 months, 6 months, then every 6 
months 
Free and acylcarnitine profile   after 3 months, 6 months, then every 6 
months 
Urine: 
calcium: creatinine ratio,  haematuria 
 
6 weeks, 3 months, 6 months, then every 6 
months 
Recommended :  
Blood: 
Vitamins A, E , B12  
 
6 months, then every 12 months  
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Zinc, selenium, copper   6 months, then every 12 months  
Folate, ferritin   6 months, then every 12 months  
 
6.4               Fine tuning 
When the ketosis doesn’t reach the adequate range (2-5mmol/l in blood) within 2 weeks after 
diet initiation and careful calculation, it is important to adjust the diet (ratio) to optimise the 
diet effect. It is also important to exclude medication, including IV, that may contain 
significant amounts of glucose or other carbohydrates. 
 
6.5               Weaning 
To stimulate oral motor activity and to avoid feeding aversion behavior, solid foods may be 
introduced at age of 4-6 months (sometimes at 9 months in the event of developmental delay). 
Combining ketogenic formula with solid food is possible while maintaining the classical diet. 
Recipes can be calculated based on the original diet ratio (3:1). This will be suitable for most 
infants (for example vegetable or fruit purees mixed with oil/margarine or fruit with double 
cream).  At the age of 9-12 months when more carbohydrate containing foods are introduced 
(such as bread, potatoes) a more liberal KD version with a low-dose of MCT is also possible 
and well tolerated. The amount of MCT is mixed with a (low fat) milk product and gradually 
increased.  
The full MCT KD (50-60 % energy MCT) allows a generous amount of protein and 
carbohydrates, but is not recommended as it is poorly tolerated in infancy 
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7.                  Diet during emergency situations. 
The increased risk of hyperketosis should be considered during intercurrent illness This is 
caused by reduced energy and carbohydrate intake in combination with elevated metabolism 
due to illness. Frequent testing of ketosis / blood glucose with use of additional carbohydrate 
as needed (additional Oral Rehydration Salt (ORS), glucose solution) is then required. 
In calculating the allowed quantity of ORS / 24 hours, the carbohydrate level of the individual 
KD will initially be assumed. This is a deciding factor for the dosage and use of ORS during 
periods of illness. When the child recovers the KD formula and/or solid foods may be 
reintroduced gradually. 
In a child established on the KD who needs to be nil by mouth and requires hydration 
intravenously for this or other reasons, solutions containing glucose should be avoided; 0.45% 
or 0.9% saline of Ringers-lactate should be utilized. Frequent testing of ketosis / blood 
glucose is required. 
If a child has an enteral feeding tube or PEG and is thought to be absorbing, then a liquid KD 
diet can be utilized as tolerated. Care needs to be given to avoid aspiration. An enteral tube 
feed can also be utilized in status epilepticus that has failed first and second line therapy [55]. 
 
8.                   Evaluation and discontinuation. 
The overall aim of treatment is to reduce, if not control, epileptic seizures. To monitor this, it 
is important for seizures to be documented in a form of a diary. Further secondary gains may 
be aimed for such as reduction of AEDs, as well as increased alertness and attention, although 
neither of these gains can be predicted. 
The aim of the treatment in case of infantile spasms (IS) varies according to the course of the 
disease. This is the most common seizure type in the first year of life. When the KD is used in 
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IS as first, second or third line treatment, the aim remains to achieve seizure freedom. After 
one month on KD, a child neurologist should then evaluate the patient to discuss the use of an 
AED in addition to KD [9]. When the KD is used in resistant IS, the overall aims are similar 
to the other drug resistant epilepsy syndromes (seizure reduction as well as the reduction of 
AEDs).  
A cognitive or psychomotor improvement is frequently observed. This has been reported by 
several studies using the KD in infants [4, 7, 9]. This outcome requires further evaluation in 
the future. The current data are limited by uncontrolled studies with small sample size. The 
data on cognitive improvement are based on the report of the parents during the clinics or 
with a questionnaire. The use of validated scales of neurodevelopment or standardized tests 
that can be repeated to evaluate alertness or attention would permit better assessment in future 
studies. 
 
8.1                Evaluation period. 
A formal evaluation of the effectiveness of the KD should be made by the ketogenic team 
(including neurologist and dietitian) in discussion with the family at any time dependent on 
the severity of the epilepsy and number of other treatment options that have previously been 
tried. Consideration should also be given to tolerance and the parent or caregiver's ability to 
comply fully with the dietary restrictions. 
There is only one study reporting when the seizures improve in responding patients on the KD 
[56]. This retrospective study evaluated the time to seizure reduction in 118 epilepsy patients 
who started on the KD of whom 84% had a seizure reduction. The first sign of improvement 
was observed after a mean time of 5 days (1-65 days). Seventy-five percent had improvement 
within the first 14 days of the diet and 90% within 23 days [56]. 
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Recommendations: the KD should be maintained for 2-3 months to undoubtedly evaluate 
efficacy. During this time a degree of fine tuning to the diet may have been required. As 
mentioned, the delay to control seizures has been described as a prognostic factor in IS. The 
patient with IS treated by KD as first, second or third treatment (aim of treatment is still 
seizure freedom) should be evaluated by the child neurologist after one month of KD to 
consider an additional treatment.  
 
8.2                Discontinuation. 
The KD is usually continued for at least 2 years in children who have seen effective seizure 
control. There is evidence that seizure control can be maintained after a return to a normal 
diet in children who have a positive response to diet therapy [57]. Children with GLUT 1 
deficiency and PDHC deficiency do not usually discontinue the KD as this will be treating the 
underlying metabolic defect. However, there is evidence that they may tolerate a reduced ratio 
(with increased carbohydrate intake) in a longer term. In the case of IS, a study randomizing 
the seizure-free patients to either discontinue the diet in the short-term (8 months)  or long 
term (2 years)  showed no difference in the rate of seizure relapse  between the two groups 
[58]. Considering the possible occurrence of side effects including growth consequences, a 
shorter duration of KD in IS might be considered. Further studies are required to confirm or 
refute this  
Weaning from KD back on to normal diet should be done gradually using a step-wise 
approach over weeks or months. The longer a child has been on KD the longer the period of 
withdrawal advised; if seizure-free the process may take 3-4 months. The ketogenic ratio will 
be slowly reduced, e.g. by 0.25, 0.5 or 1.0 every few days, weeks, or more slowly, e.g. every 
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month. However, if there has been no benefit from the diet a full wean within 2 weeks is 
possible, especially in the young infant who needs to move quickly to the next treatment 
option. Ketone levels can be monitored during this time and once they are no longer present 
in blood or urine tests the transition to normal diet can be made more quickly. This process 
can be an anxious time for parents or caregivers who may need reassurance and support. If at 
any point there is deterioration in seizure control the child can go back to the last ratio used. 
Concentrated sources of refined carbohydrate should only be reintroduced cautiously once the 
child is fully established on a normal diet without ill effects.  
 
9.                   Conclusions and remarks for future research. 
These guidelines represent the first international effort to identify commonalities in the 
clinical use of the KD in infants. All members of the project and review group agreed on most 
of the major issues in both choosing the best candidates for the KD, pre-diet counseling, 
supplementation, and the management of children on the KD in regards to nutrition, 
laboratory values, potential adverse effects, and eventual discontinuation. Areas of variability 
included choice of initial diet ratio, how to initiate the KD and how to design the nutritional 
composition of the KD to reach adequate ketosis, with respect to the specific requirements of 
the infant. 
 
The creation of these recommendations for use in infants encourages safe and effective 
implementation of the KD in this vulnerable group of patients . 
 
Future research should focus on effects of seizure reduction in specific underlying conditions, 
how to minimize adverse effects to prevent discontinuation and how to optimize growth of the 
infant. 
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Supplementary data        Summary of reported adverse effects of KD in infants.  
Study Infant population Adverse effects  
Nordli et al, 
2001 
Retrospective 
review  
32 infants  
< 24 months 
Mean age KD 
initiation 14 
months 
6/32 (19%): 
Coma due to hypoglycaemia and acidosis post 
initiation– n=1, Vomiting – n=1, Renal stone – n=1,  
Gastro-intestinal bleed (erosive oesophagitis from NG 
tube) – n=1-Hyperlipidaemia – n=1,  
Ulcerative colitis – n=1 
Goyens et al, 
2002 
Single case 
report  
KD initiated at  
13 days in  
GLUT1 DS 
neonate  
Weight loss and malnutrition associated with low lipase 
activity, treated with pancreatic enzymes and use of 
MCT. 
Eun et al, 2006 
Retrospective 
review  
43 infants aged 6-
42 months with 
infantile spasms 
Mean age KD 
initiation 19 
months  
24/43 (56%): 
Gastrointestinal disturbances – n=8 (1 within 4 weeks) 
Serious infectious disease – n=4  
Severe dehydration – n=3 (2 within 4 weeks) 
Pneumonia – n=3 (1 lipoid aspiration, 2 within 4 weeks) 
Renal stone – n=2, Haematuria with hypercalcuria – n=1 
Reflux oesophagitis – n=1, Erosive gastritis – n=1,  
Fatty liver – n=1 
Kossoff et al, 
2008 
Retrospective 
review  
13 infants <12 
months treated 
with KD as first 
line for infantile 
spasms 
Median age of 
spasms onset – 5 
months 
4/13 (31%): 
Gastro oesophageal reflux –n= 1 
Constipation – n=1 
Poor tolerance of formula –n= 1 
Weight loss –n= 1 
Hong et al, 
2010 
Prospective 
study  
104 infants with 
infantile spasms 
Mean age KD 
initiation 1.2 years 
34/104 (33%): 
Dyslipidaemia – n=17, Constipation – n=7,  
Gastro oesophageal reflux – n=6,  
Behavioural problems – n=3, Haematuria – n=3,  
Diarrhea – n=3, Renal stone – n=3, Acidosis – n=3, 
Hair thinning – n=2, , Hypercalcaemia – n=2,  
Dry skin – n=1, Pica – n=1 
 
 
Numis et al, 
2011 
Retrospective 
review  
26 infants with 
infantile spasms 
Mean age KD 
initiation 19 
months 
6/26 (23%): 
Irritability, lethargy, decreased appetite, persistent 
hypoglycaemia, renal stone, vitamin D deficiency  
(numbers not specified) 
Pires et al, 2013 
Prospective 
study  
17 infants with 
infantile spasms, 
16<12 months 
Mean age KD 
initiation 9 months 
Weight loss and dyslipidemia (raised triglycerides) in 
some infants 
Kayyali et al, 
2014 
Prospective 
study  
20 infants with 
infantile spasms 
Mean age KD 
initiation 1.2 years 
(0.3-2.9 years) 
12/20 (60%): 
Constipation – n=7, Acidosis – n=4,  
Minor dyslipidemia - n=3, Diarrhea – n=1,  
Urinary sediment- n=1 
Dressler et al, 
2015 
Retrospective 
study  
58 infants  
< 18 months,  
(42 <9 months) 
Mean age KD 
initiation 0.68 
years (0.15-1.5 
years) 
29/58 (50%): 
Carnitine deficiency – n=4, kidney stones – n=3,  
Minor dyslipidemia - n=21 Weight gain– n=1,  
Growth deficiency- n=3, high cholesterol – n=2 
 
 
 
